Literature DB >> 17991539

High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates.

Kamran P Sajadi1, Timothy Kim, Martha K Terris, James A Brown, Ronald W Lewis.   

Abstract

OBJECTIVES: Men with previously negative prostate biopsies but continued suspicion for carcinoma present a diagnostic dilemma often managed by saturation prostate biopsy (SPB). We sought to determine the patient characteristics for which repeat biopsy by SPB provides the greatest utility for prostate cancer detection.
METHODS: The records of the men at the state hospital and affiliated Veterans Affairs Medical Center with previously negative prostate biopsy findings who had then undergone SPB were reviewed. The predictors of cancer were analyzed, and those that were significant were included in a multivariate logistic regression model.
RESULTS: A total of 82 men underwent SPB from November 2001 to March 2006. Their mean age was 61 years (range 43 to 76), and 44 (54%) were white, 37 (45%) were African American, and 1 (1%) was Asian. The mean prostate-specific antigen level at SPB was 9.1 ng/mL (range 1.0 to 34). The number of prior biopsies was one in 43 patients (52%) and two or more in 39 patients (47%). The prostate volume averaged 53 cm(3) (range 12 to 200). SPB included a median of 24 cores (range 24 to 40). Of the 82 patients, 16 (19.5%) were diagnosed with cancer, of whom 10 (63%) elected to undergo radical prostatectomy. The only significant predictors of prostate cancer were the prostate-specific antigen level (P = 0.009) and prostate volume. The cancer detection rate was 57% for patients with a prostate volume less than 37 cm(3) and 7% for those with larger glands, and the difference was significant on multivariate analysis (odds ratio 31, 95% confidence interval 6 to 158, P <0.0001).
CONCLUSIONS: The results of our study have shown that SPB is an effective diagnostic tool with a high yield for men with persistent suspicion for prostate cancer, prior negative biopsy findings, and a prostate volume less than 37 cm(3).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991539     DOI: 10.1016/j.urology.2007.05.017

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach.

Authors:  Peter H Gann; Angela Fought; Ryan Deaton; William J Catalona; Edward Vonesh
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

Review 2.  Strategies for repeat prostate biopsies.

Authors:  Martha K Terris
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

3.  Limitations of a contemporary prostate biopsy: the blind march forward.

Authors:  John T Wei
Journal:  Urol Oncol       Date:  2010 Sep-Oct       Impact factor: 3.498

Review 4.  Risk-based prostate cancer screening.

Authors:  Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers
Journal:  Eur Urol       Date:  2011-11-24       Impact factor: 20.096

Review 5.  Random biopsy: when, how many and where to take the cores?

Authors:  Vincenzo Scattoni; Carmen Maccagnano; Umberto Capitanio; Andrea Gallina; Alberto Briganti; Francesco Montorsi
Journal:  World J Urol       Date:  2014-06-08       Impact factor: 4.226

6.  Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection.

Authors:  Tomonori Kato; Akira Komiya; Akihiro Morii; Hiroaki Iida; Takatoshi Ito; Hideki Fuse
Journal:  Oncol Lett       Date:  2016-06-09       Impact factor: 2.967

Review 7.  A review of optimal prostate biopsy: indications and techniques.

Authors:  Justin Streicher; Brian Lee Meyerson; Vidhya Karivedu; Abhinav Sidana
Journal:  Ther Adv Urol       Date:  2019-08-28

8.  Repeat prostate biopsy strategies after initial negative biopsy: meta-regression comparing cancer detection of transperineal, transrectal saturation and MRI guided biopsy.

Authors:  Adam W Nelson; Rebecca C Harvey; Richard A Parker; Christof Kastner; Andrew Doble; Vincent J Gnanapragasam
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

9.  Low incidence of prostate cancer identified in the transition and anterior zones with transperineal biopsy.

Authors:  Teresa L Danforth; K Kent Chevli; Louis Baumann; Michael Duff
Journal:  Res Rep Urol       Date:  2012-12-05

Review 10.  Optimal biopsy approach for detection of clinically significant prostate cancer.

Authors:  Simona Ippoliti; Peter Fletcher; Luca Orecchia; Roberto Miano; Christof Kastner; Tristan Barrett
Journal:  Br J Radiol       Date:  2021-08-06       Impact factor: 3.039

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.